PASITHEA THERAPEUTICS CORP. Operating Cash Flow
PASITHEA THERAPEUTICS CORP. (KTTA) reported Operating Cash Flow of -$9.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- PASITHEA THERAPEUTICS CORP. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$4.71M.
- PASITHEA THERAPEUTICS CORP. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.79M.
- PASITHEA THERAPEUTICS CORP. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$5.40M.
- PASITHEA THERAPEUTICS CORP. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.89M.
- PASITHEA THERAPEUTICS CORP. net cash provided by (used in) operating activities for fiscal 2025 was -$15.21M.
- PASITHEA THERAPEUTICS CORP. net cash provided by (used in) operating activities for fiscal 2024 was -$13.92M.
- PASITHEA THERAPEUTICS CORP. net cash provided by (used in) operating activities for fiscal 2022 was -$14.56M.
- PASITHEA THERAPEUTICS CORP. net cash provided by (used in) operating activities for fiscal 2021 was -$3.17M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 5 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 8 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$4.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$9.49M 10-Q · filed 2026-08-14 | -$14.89M derived: sum of 3 quarters · filed 2026-08-14 | -$17.78M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | -$4.79M 10-Q · filed 2026-05-15 | -$10.18M derived: sum of 2 quarters · filed 2026-05-15 | -$13.07M derived: sum of 3 quarters · filed 2026-05-15 | -$16.94M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | -$5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$8.29M derived: sum of 2 quarters · filed 2026-03-30 | -$12.16M derived: sum of 3 quarters · filed 2026-08-14 | -$15.21M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | -$2.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$6.76M derived: sum of 2 quarters · filed 2026-08-14 | -$9.81M 10-Q · filed 2025-11-13 | -$12.26M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | -$3.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$6.92M 10-Q · filed 2026-08-14 | -$9.37M derived: sum of 3 quarters · filed 2026-08-14 | -$12.49M derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | -$3.06M 10-Q · filed 2026-05-15 | -$5.50M derived: sum of 2 quarters · filed 2026-05-15 | -$8.62M derived: sum of 3 quarters · filed 2026-05-15 | -$12.66M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | -$2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$5.56M derived: sum of 2 quarters · filed 2026-03-30 | -$9.60M derived: sum of 3 quarters · filed 2026-03-30 | -$13.92M 10-K · filed 2026-03-30 | ||
| 2024-09-30 | -$3.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$7.16M derived: sum of 2 quarters · filed 2025-11-13 | -$11.48M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | -$4.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$8.36M 10-Q · filed 2025-08-14 | ||||
| 2024-03-31 | -$4.32M 10-Q · filed 2025-05-15 | |||||
| 2022-12-31 | -$4.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$9.66M derived: sum of 2 quarters · filed 2023-03-30 | -$12.03M derived: sum of 3 quarters · filed 2023-03-30 | -$14.56M 10-K · filed 2023-03-30 | ||
| 2022-09-30 | -$5.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$7.62M derived: sum of 2 quarters · filed 2022-11-14 | -$10.14M 10-Q · filed 2022-11-14 | -$11.89M derived: sum of 4 quarters · filed 2023-03-30 | ||
| 2022-06-30 | -$2.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$4.90M 10-Q · filed 2022-08-15 | -$6.65M derived: sum of 3 quarters · filed 2023-03-30 | -$7.20M derived: sum of 4 quarters · filed 2023-03-30 | ||
| 2022-03-31 | -$2.53M 10-Q · filed 2022-05-16 | -$4.27M derived: sum of 2 quarters · filed 2023-03-30 | -$4.82M derived: sum of 3 quarters · filed 2023-03-30 | -$5.32M derived: sum of 4 quarters · filed 2023-03-30 | ||
| 2021-12-31 | -$1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$2.29M derived: sum of 2 quarters · filed 2023-03-30 | -$2.79M derived: sum of 3 quarters · filed 2023-03-30 | -$3.17M 10-K · filed 2023-03-30 | ||
| 2021-09-30 | -$548.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.05M derived: sum of 2 quarters · filed 2022-11-14 | -$1.43M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | -$499.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$881.28K 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | -$381.85K 10-Q · filed 2022-05-16 | |||||
| 2020-12-31 | -$38.69K 10-K · filed 2022-03-30 | |||||
| 2020-09-30 | -$23.97K 10-Q · filed 2021-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |